INTRODUCTION {#s1}
============

Esophageal cancer is one of the most common cancers worldwide, with approximately 456,000 new cases and 400,000 deaths in 2012 \[[@R1], [@R2]\]. Esophageal squamous cell carcinoma (ESCC) is the most prevalent esophageal cancer in the world, especially in Asian countries \[[@R3], [@R4]\]. ESCC is highly invasive and rapidly metastatic, often resulting in a poor postoperative quality of life \[[@R5], [@R6]\]. In spite of clinical advances in the field of oncology, the overall long-term survival rates of ESCC remain dismal \[[@R7]\]. If patients were diagnosed and treated at an early stage, the five-year survival rate after endoscopic mucosectomy could reach 100% \[[@R8]\]. Therefore, there is an urgent need to identify sensitive and specific biomarkers for the early diagnosis of ESCC.

One of the early events that occur during carcinogenesis are the epigenetic changes \[[@R9], [@R10]\]. Epigenetic modifications cause heritable changes to cells without changes to DNA sequence. Epigenetic modifications, such as methylation, histone modifications, DNA replication timing, nucleosome positioning, or heterochromatization, result in selective gene expression or repression \[[@R9], [@R11]\]. DNA methylation is one of the most extensively characterized epigenetic modifications \[[@R12], [@R13]\]. Aberrant DNA methylation has been associated with various human diseases, including cancer \[[@R14]\], autoimmune diseases \[[@R15]\], mental illness \[[@R16]\], and cardiovascular diseases \[[@R17]\]. Large-scale methylation analysis of human genomic DNA may provide a better understanding of the molecular mechanisms involved in the esophageal carcinogenesis \[[@R18]\].

In this epidemiological study, we analyzed the impact of aberrant DNA methylation levels on the clinical and pathological features of ESCC in a Chinese population, and we investigated the methylation profile as a potential biomarker for the diagnosis of esophageal cancer.

RESULTS {#s2}
=======

Identification of candidate genes {#s2_1}
---------------------------------

The heat map of hierarchical clustering of methylation according to the data from the Infinium Methylation 450K array is shown in [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}. Based on diffScore, delta β and gene function, we selected 16 candidate genes (*RASSF1, PIK3R1, ITGAV, NFKB1, TAP2, APC, BRCA1, CCND1, CDH1, CDKN2A, BNIP3, HTATIP2, PRDM16, PTEN, PTX3* and *SOCS1*) for validation ([Supplementary Figure S2](#SD2){ref-type="supplementary-material"}).

Validation of methylated CpG sites {#s2_2}
----------------------------------

We collected 43 cancer lesion samples, 43 remote normal-appearing esophageal tissues, and 10 healthy control tissues. The patients included 28 males and 15 females, with the age ranging from 46 to 81 years (Table [1](#T1){ref-type="table"}). We also recruited 10 healthy controls, including 7 males and 3 females, with the age ranging from 42 to 74 years (mean ± standard deviation: 58.8 ± 9.2 years). We sequenced 1160 CpG sites in the promoter region of 16 candidate genes. After excluding loci with low calling rate, 961 CpG sites in 15 genes met the requirements for further analysis (Table [2](#T2){ref-type="table"}). There were 33.82% (325/961) CpG sites showing significant differences in the distribution of methylation between ESCC and normal esophageal tissues (*P \<* 0.05). The proportion of differentially methylated sites in each gene is shown in Figure [1](#F1){ref-type="fig"}. There were 195 sites having 2 to 10 fold changes and 58 sites having more than 10 fold changes between ESCC and normal esophageal tissues. 299 out of differentially methylated 325 CpG sites (92 %) had higher methylation level in ESCC samples compared with healthy controls. In addition, 254 CpG sites had significantly different methylation between remote normal-appearing tissues and health controls, and 221 CpG sites had significantly different methylation status between ESCC and remote normal-appearing tissues. The above results are summarized in a Venn diagram in Figure [2](#F2){ref-type="fig"}. There were 64 CpG sites differentially methylated between these three groups (cancer lesions, remote normal-appearing samples, and health controls). Among them, 54 CpG sites were located in the gene of *PRDM16*.

###### Clinical characteristics of patients

  No.   Gender   Age   Tumor location   Smoking   Drinking   TNM      G stage (histologic grade)
  ----- -------- ----- ---------------- --------- ---------- -------- ----------------------------
  1     Female   78    Lower            No        No         T2N0M0   G3
  2     Female   68    Lower            No        No         T1N0M0   G2
  3     Male     72    Middle           Yes       No         T1N0M0   G2
  4     Male     64    Middle           Yes       Yes        T3N1M0   G2
  5     Male     69    Middle           No        No         T2N0M0   G2
  6     Male     62    Middle           No        No         T3N0M0   G2
  7     Male     57    Middle           Yes       Yes        T4N0M0   G2
  8     Female   58    Upper            No        No         T2N1M0   G2
  9     Female   73    Upper            No        No         T3N0M0   G2
  10    Female   68    Middle           No        No         T3N1M0   G2
  11    Female   68    Upper            No        No         T3N1M0   G2
  12    Female   69    Middle           No        No         T2N1M0   G2
  13    Female   64    Middle           No        No         T1N0M0   G2
  14    Male     64    Lower            Yes       Yes        T2N2M0   G2
  15    Female   61    Lower            No        No         T3N1M0   G3
  16    Male     75    Middle           Yes       No         T3N1M0   G3
  17    Male     54    Middle           Yes       No         T3N0M0   G1
  18    Female   65    Middle           No        No         T2N0M0   G2
  19    Male     54    Lower            Yes       Yes        T3N1M0   G2
  20    Male     62    Middle           No        No         T3N1M0   G3
  21    Male     78    Middle           Yes       No         T3N1M0   G2
  22    Male     63    Middle           Yes       No         T2N0M0   G3
  23    Female   76    Upper            Yes       Yes        T1N0M0   G2
  24    Male     59    Middle           Yes       Yes        T2N1M0   G3
  25    Female   60    Middle           No        No         T2N1M0   G2
  26    Male     67    Middle           No        No         T2N0M0   G3
  27    Male     60    Middle           No        No         T2N1M0   G3
  28    Male     60    Middle           No        No         T3N1M0   G3
  29    Male     67    Middle           Yes       Yes        T3N0M0   G2
  30    Male     46    Middle           Yes       Yes        T3N1M0   G2
  31    Male     81    Middle           No        Yes        T2N0M0   G2
  32    Male     61    Middle           No        Yes        T1N1M0   G3
  33    Male     46    Middle           No        No         T3N1M0   G3
  34    Male     65    Middle           Yes       Yes        T3N1M0   G2
  35    Female   70    Middle           No        No         T3N1M0   G3
  36    Male     67    Lower            No        No         T1N0M0   G3
  37    Female   60    Upper            No        No         T1N0M0   G2
  38    Male     64    Lower            No        Yes        T3N0M0   G2
  39    Male     77    Lower            Yes       No         T3N1M0   G2
  40    Male     74    Middle           Yes       Yes        T3N2M0   G3
  41    Male     71    Lower            Yes       Yes        T3N3M0   G3
  42    Female   71    Middle           No        No         T1N0M0   G2
  43    Male     60    Middle           Yes       Yes        T2N1M1   G2

###### Sequenced sites of selected genes

  Genes        Fragment              Start/Stop            Size (bp)   Number of CpG sites
  ------------ --------------------- --------------------- ----------- ---------------------
  RASSF1       RASSF1_M1             50377767/50378028     261         21
  RASSF1_M2    50378005/50378218     213                   23          
  RASSF1_M3    50378194/50378472     278                   27          
  RASSF1_M5    50375039/50375295     256                   23          
  RASSF1_M6    50374899/50375126     227                   19          
  RASSF1_M7    50374706/50374925     219                   29          
  RASSF1_M9    50374301/50374516     215                   13          
  PIK3R1       PIK3R1_M2             67511168/67511412     244         22
  PIK3R1_M4    67511596/67511806     210                   23          
  PIK3R1_M5    67511286/67511520     234                   21          
  PIK3R1_M6    67511047/67511305     258                   22          
  PIK3R1_M7    67512226/67512438     212                   18          
  PIK3R1_M8    67584255/67584471     216                   15          
  ITGAV        ITGAV_M1              187454700/187454960   260         21
  ITGAV_M2     187454936/187455177   241                   32          
  ITGAV_M3     187455157/187455369   212                   21          
  NFKB1        NFKB1_M2              103422534/103422795   261         37
  NFKB1_M3     103422775/103422981   206                   23          
  NFKB1_M4     103423077/103423302   225                   18          
  TAP2         TAP2_M1               32806418/32806681     263         12
  APC          APC_M2                112073375/112073585   210         15
  BRCA1        BRCA1_M1              41275281/41275523     242         18
  BRCA1_M3     41275011/41275281     270                   11          
  BRCA1_M4     41275268/41275528     260                   12          
  CCND1        CCND1_M3              69458670/69458890     220         14
  CDKN2A       CDKN2A-2              21993123/21993331     208         20
  CDKN2A-4     21993770/21993957     187                   16          
  CDKN2A-6     21994239/21994504     265                   26          
  CDKN2A-7     21994477/21994700     223                   11          
  CDKN2A_M8    21972954/21973198     244                   11          
  CDKN2A_M9    21974670/21974872     202                   15          
  CDKN2A_M10   21974852/21975095     243                   20          
  BNIP3        BNIP3-1               133795927/133796159   232         10
  BNIP3-3      133796371/133796631   260                   33          
  BNIP3-6      133797020/133797250   230                   26          
  BNIP3-7      133797230/133797402   172                   16          
  HTATIP2      HTATIP2-1             20385087/20385355     268         24
  HTATIP2-2    20385336/20385546     210                   20          
  PRDM16       PRDM16-1              2983847/2984081       234         14
  PRDM16-5     2984736/2984979       243                   29          
  PRDM16-7     2985182/2985386       204                   19          
  PRDM16-8     2985367/2985573       206                   16          
  PRDM16-9     2985553/2985775       222                   19          
  PTEN         PTEN-1                89623758/89624026     268         21
  PTX3         PTX3-1                157155257/157155524   267         9
  PTX3-2       157155500/157155711   211                   25          
  SOCS1        SOCS1-1               11349069/11349310     241         20
  SOCS1-3      11349540/11349759     219                   31          

![Percent of differentially methylated sites in each candidate gene](oncotarget-08-679-g001){#F1}

![Venn diagram summarizing the differentially methylated sites\
Red circle indicates differentially methylated sites between cancer and healthy control tissues; yellow circle indicates differentially methylated sites between cancer and remote normal-appearing tissue; green circle indicates differentially methylated sites between remote normal-appearing and healthy control tissues.](oncotarget-08-679-g002){#F2}

Diagnostic value analysis {#s2_3}
-------------------------

We further analyzed the cumulative methylation levels by considering multiple CpG sites in each gene. The diagnostic values of selected CpG sites and genes were estimated based on three different models.

Model 1 {#s2_4}
-------

We calculated the cumulative methylation by summarizing the frequency of all CpG sites in each gene. Nine genes (*APC, BNIP3, BRCA1, CCND1, CDKN2A, HTATIP2, ITGAV, PRDM16* and *TAP2*) showed significantly different cumulative methylation levels among the three groups. The methylation levels of *APC, ITGAV, PRDM16* and *PTX3* were significantly different between esophageal cancer and healthy control tissues (Table [3](#T3){ref-type="table"}). The AUC (95% CI) of each gene in the diagnosis of ESCC is listed in Table [4](#T4){ref-type="table"}. The *PRDM16* gene showed the highest diagnostic value with the AUC (95% CI) of 0.958 (0.906--1.000), followed by *ITGAV*, with the AUC (95% CI) of 0.779 (0.651--0.907).

###### Comparison of cumulative methylation levels of multiple CpG sites in each gene using different models

  Gene      Model A   Model B   Model C                                                                                                                                                                                               
  --------- --------- --------- --------- -------- --------- ------- --------- --------- -------- -------- -------- --------- --------- --------- --------- --------- ------- ------- -------- -------- --------- --------- --------- ---------
  APC       0.108     0.118     0.199     6.739    0.034     0.355   0.405     0.04      \-       \-       \-       \-        \-        \-        \-        \-        \-      \-      \-       \-       \-        \-        \-        \-
  BNIP3     6.902     8.833     8.041     9.57     0.008     0.045   0.031     1         1.251    2.505    2.579    18.411    \<0.001   \<0.001   1         \<0.001   1.251   2.505   2.579    18.411   \<0.001   \<0.001   1         \<0.001
  BRCA1     22.537    22.669    20.809    14.314   0.001     1       \<0.001   0.475     10.075   9.99     9.038    32.385    \<0.001   1         \<0.001   0.001     0.88    0.898   0.896    6.655    0.036     0.03      1         0.114
  CCND1     0.134     0.144     0.133     7.392    0.025     0.265   0.033     1         0.004    0.008    0.008    8.725     0.013     0.013     1         0.017     0.004   0.008   0.008    8.725    0.013     0.013     1         0.017
  CDKN2A    5.913     6.941     7.23      15.116   0.001     0.055   0.001     1         1.718    2.183    2.662    10.386    0.006     0.102     0.009     1         0.352   0.905   1.68     20.527   \<0.001   \<0.001   1         \<0.001
  HTATIP2   0.363     0.525     0.527     8.63     0.013     0.01    1         0.052     0.082    0.155    0.17     16.578    \<0.001   \<0.001   1         \<0.001   0.082   0.155   0.17     16.578   \<0.001   \<0.001   1         \<0.001
  ITGAV     0.614     0.715     0.722     10.101   0.006     0.005   1         0.013     0.029    0.059    0.065    14.9      0.001     0.003     1         \<0.001   0.029   0.059   0.065    14.9     0.001     0.003     1         \<0.001
  NFKB1     0.687     0.777     0.942     1.731    0.421     \-      \-        \-        0.007    0.042    0.058    14.347    0.001     0.001     1         0.001     0.007   0.042   0.058    14.347   0.001     0.001     1         0.001
  PIK3R1    1.291     1.357     1.969     2.422    0.298     \-      \-        \-        0.057    0.153    0.213    22.693    \<0.001   \<0.001   0.576     \<0.001   0.041   0.142   0.204    25.481   \<0.001   \<0.001   0.376     \<0.001
  PRDM16    9.155     13.202    20.756    35.643   \<0.001   0.003   0.001     \<0.001   6.724    10.686   18.062   36.8949   \<0.001   0.003     \<0.001   \<0.001   5.86    9.867   17.251   37.181   \<0.001   0.002     \<0.001   \<0.001
  PTEN      0.381     0.534     1.666     5.182    0.075     \-      \-        \-        0.374    0.53     1.659    4.886     0.087     \-        \-        \-        0.374   0.53    1.659    4.886    0.087     \-        \-        \-
  PTX3      0.468     1.053     1.649     0.947    0.623     \-      \-        \-        0.301    0.222    0.391    6.239     0.044     0.125     1         0.037     0.03    0.222   0.391    6.239    0.044     0.125     1         0.037
  RASSF1    2.535     3.482     8.962     3.598    0.165     \-      \-        \-        1.804    2.71     6.898    2.871     0.238     \-        \-        \-        1.803   2.71    6.898    2.871    0.238     \-        \-        \-
  SOCS1     1.328     2.321     2.391     3.888    0.143     \-      \-        \-        0.085    0.276    0.316    5.436     0.066     \-        \-        \-        0.084   0.276   2.338    5.436    0.066     \-        \-        \-
  TAP2      5.712     5.719     5.362     32.904   \<0.001   1       \<0.001   0.003     2.369    2.325    2.152    44.501    \<0.001   0.301     \<0.001   \<0.001   \-      \-      \-       \-       \-        \-        \-        \-

N: healthy control tissues; A: remote normal-appearing tissues; T: cancer tissue

###### Diagnostic values of selected genes for esophageal cancer using different models

  Gene      No. of sample   Model A   Model B   Model C                                                                            
  --------- --------------- --------- --------- -------------- ---------- ------- -------------- ---------- ------- -------------- ----------
  APC       43              10        0.73      0.535-0.925    0.024      --      --             --         --      --             --
  BNIP3     43              10        0.556     0.388-0.723    0.585      0.856   0.749-0.962    0.001      0.876   0.775-0.978    \< 0.001
  BRCA1     43              10        0.326     0.180-0.471    0.088      0.13    0.033--0.228   \< 0.001   0.712   0.529--0.895   0.039
  CCND1     43              10        0.521     0.301--0.741   0.838      0.799   0.648--0.949   0.003      0.817   0.667--0.966   0.002
  CDKN2A    43              10        0.437     0.290--0.585   0.539      0.451   0.301--0.601   0.633      0.912   0.832--0.992   \< 0.001
  HTATIP2   43              10        0.698     0.558--0.837   0.053      0.872   0.766--0.978   \< 0.001   0.881   0.779--0.983   \< 0.001
  ITGAV     43              10        0.779     0.651--0.907   0.006      0.879   0.783--0.975   \< 0.001   0.898   0.807--0.988   \< 0.001
  NFKB1     43              10        0.605     0.430--0.779   0.306      0.855   0.753--0.956   0.001      0.869   0.772--0.966   \< 0.001
  PIK3R1    43              10        0.635     0.464--0.806   0.187      0.93    0.863--0.998   \< 0.001   0.969   0.928--1.000   \< 0.001
  PRDM16    43              10        0.958     0.906--1.000   \< 0.001   0.967   0.921--1.000   \< 0.001   0.988   0.965--1.000   \< 0.001
  PTEN      43              10        0.663     0.491--0.835   0.112      0.66    0.491--0.830   0.117      0.675   0.505--0.845   0.088
  PTX3      43              10        0.593     0.430--0.756   0.363      0.737   0.604--0.871   0.02       0.749   0.617--0.880   0.015
  RASSF1    43              10        0.681     0.528--0.835   0.076      0.66    0.488--0.833   0.117      0.676   0.502--0.850   0.086
  SOCS1     43              10        0.628     0.472--0.784   0.211      0.74    0.600--0.897   0.019      0.752   0.615--0.890   0.014
  TAP2      43              10        0.14      0.031--0.248   \< 0.001   0.028   0.000--0.066   \< 0.001   --      --             --

Model 2 {#s2_5}
-------

By excluding non-significantly differentiated CpG sites, we calculated the cumulative methylation by summarizing the frequency of significant CpG sites in each gene. Eleven genes (*BNIP3, BRCA1, CCND1, CDKN2A, HTATIP2, ITGAV, NFKB1, PIK3R1, PRDM16, PTX3* and *TAP2*) showed significant differences in methylation between groups. The number of differently methylated genes increased to 10 (*BNIP3, BRCA1, CCND1, HTATIP2, ITGAV, NFKB1, PIK3R1, PRDM16, PTX3* and *TAP2*) between ESCC and healthy control tissues (Table [3](#T3){ref-type="table"}). The AUC values (95% CI) of each gene in the diagnosis of ESCC are listed in Table [4](#T4){ref-type="table"}. Methylation of *PRDM16* gene had the highest diagnostic value, with the AUC (95% CI) of 0.967 (0.921--1.000), followed by *PIK3R1*, with the AUC (95% CI) of 0.930 (0.863--0.998).

Model 3 {#s2_6}
-------

We further excluded CpG sites with negative correlations and kept 299 sites for analysis. Ten genes (*BNIP3, BRCA1, CCND1, CDKN2A, HTATIP2, ITGAV, NFKB1, PIK3R1, PRDM16* and *PTX3*) had significantly different methylation status among the three groups. The methylation levels of *BNIP3, CCND1, CDKN2A, HTATIP2, ITGAV, NFKB1, PIK3R1, PRDM16* and *PTX3* were significantly different between esophageal cancer and healthy control tissues (Table [4](#T4){ref-type="table"}). The AUC (95% CI) of each gene in the diagnosis of ESCC is listed in Table [4](#T4){ref-type="table"}. The methylation of PRDM16 gene showed the highest diagnostic value, with the AUC (95% CI) of 0.988 (0.965--1.000), followed by *PIK3R1*, with the AUC (95% CI) of 0.969 (0.928--1.000). Compared with findings using model 1 and model 2, the AUC of each gene in model 3 has greatly increased. Especially for *BRCA1* and *CDKN2A*, the AUC increased from less than 0.5 to 0.712 and 0.912, respectively. Based on the model 3, the cumulative methylation level of most genes increased with the histologic changes from normal to normal-appearing tissues and cancer lesions (Figure [3](#F3){ref-type="fig"}). To avoid false positives caused by multiple comparisons between groups, we used the Bonferroni correction method. Using Bonferroni correction, 49 CpG sites in 4 genes were significant, including 1 site in *BNIP3*, 1 site in *PIK3R1*, 46 sites in *PRDM16*, and 1 site in *SOCS1*. The cumulative methylation levels of *PRDM16* were significantly different among the three groups (F = 38.445, *P \<* 0.001). The AUC of *PRDM16* was 0.963 (95% CI: 0.914--1.000).

![The cumulative methylation levels of multiple CpG sites in each gene](oncotarget-08-679-g003){#F3}

Methylation status and clinical characteristics {#s2_7}
-----------------------------------------------

The methylation frequency was higher in patients at advanced cancer stages. For example, samples from patients with N1-3 stage had an average cumulative methylation value of 9.56 in *RASSF1* gene, which was significantly higher than that in patients at N0 stage (cumulative methylation value: 3.54). For *HTATIP2* gene, samples from patients at G1-2 stages also had a significantly higher cumulative methylation level compared with patients at G3 stage (*P \<* 0.05, Figure [4](#F4){ref-type="fig"}). The cumulative methylation levels of these genes did not correlate with patient\'s gender (male and female) and age (\< 60 and \>= 60 years).

![The relationship between clinical characteristics and DNA methylation in cancer lesions](oncotarget-08-679-g004){#F4}

Protein expression and methylation status {#s2_8}
-----------------------------------------

Next, we analyzed protein levels of RASSF1, PIK3R1 and PTEN by immunohistochemistry. In the esophageal cancer lesions, PIK3R1 was expressed in 65.5% (19/29) cases (+: 18; ++: 1; +++: 0), PTEN was expressed in 48.3% (15/31) cases (+: 14; ++: 1; +++: 0), and RASSF1 was expressed in 56.7% (17/30) cases (+: 14; ++: 3; +++: 0). We observed a negative correlation between the methylation level and the IOD, but the coefficient was not significant (*RASSF1*: r = −0.122, *P* = 0.521; *PIK3R1*: r = −0.215, *P* = 0.264; *PTEN*: r = −0.095, *P* = 0.619). The methylation level of *RASSF1* gene was significantly higher in samples with negative expression than in samples with positive expression (*P* = 0.022).

DISCUSSION {#s3}
==========

When cancer occurs, a massive global hypomethylation is frequently observed, while certain genes can be hypermethylated at the CpG islands \[[@R19]\]. Previous studies have indicated aberrant DNA methylation in esophageal cancer; however, those studies have focused on limited CpG sites \[[@R20]--[@R22]\]. In this study, we used a two-stage study design, sequenced 1160 CpG sites in the promoter region of 16 candidate genes, and demonstrated that aberrant DNA methylation can be a potential biomarker for esophageal cancer.

Compared with other methods, such as MSP, Q-PCR, MethyLight or bisulfite pyrosequencing, NGS used in this study can capture full sample diversity with small amounts of DNA. In addition, NGS can enhance epigenetic analyses with high coverage density and flexibility, which help advance our understanding of epigenetics at the genomic level \[[@R23]\]. A fluorescently labeled reversible terminator is utilized in this system, allowing for the accrual of qualitative and quantitative information of nucleic acid at an incredible throughput while incurring relatively limited costs \[[@R24]\].

One of the most robust epigenetic marks found in this study was *PRDM16* gene. *PRDM16* is located near the 1p36.3 breakpoint, encoding a zinc finger transcription factor and contains an N-terminal PR domain. It is known to be a fusion partner of *RPN1, RUNX1* and other genes in hematopoietic malignancies \[[@R25]\]. The malfunction of *PRDM16* is related to a poor prognosis of cancer patients \[[@R26]\]. For example, *PRDM16* is often methylated in lung cancer cells, with downregulated protein expression \[[@R27]\]. The demethylation drug 5-aza-2′-dC upregulates PRDM16 expression and suppresses growth of lung cancer cells \[[@R27]\].

Other genes with a higher AUC (over 0.9) for distinguishing ESCC were *PIK3R1* and *CDKN2A*. *PIK3R1* encodes a p85 regulatory subunit alpha and appears to play a tumor suppressor role because PI3K subunit p85α (p85α) regulates and stabilizes p110α \[[@R28]\]. A previous study has reported that the expression of *PRK3R1* negatively correlates with hypermethylation of CpG sites in *PIK3R1* \[[@R29]\]. Our results also showed similar negative correlations, although they were not statistically significant; this may be due to the limited sample size. CDKN2A blocks phosphorylation of the Rb protein and inhibits cell cycle progression. *CDKN2A* is aberrantly methylated in esophageal cancer \[[@R30]\], and is associated with metastatic and invasive phenotypes \[[@R31]\]. Similar *CDKN2A* methylation patterns have been observed in gastric and nasopharyngeal carcinoma \[[@R32], [@R33]\]. As the regional lymph node metastasis is associated with the patient\'s prognosis, the methylation status of these genes might be used to assess the possibility of recurrence and metastasis of ESCC patients and also help to implement proper medications. Moreover, our study shows that the methylation levels of selected genes, such as *RASSF1* and *HTATIP2,* change with the cancer stages, indicating their potential values in the prognosis of ESCC.

There are several limitations in this study. First, the bisulfite conversion efficiency is critical for the accuracy and the reliability of the results. The incomplete conversion of unmethylated cytosine to uracil or inappropriate conversion of methylcytosine to thymine can cause over- or underestimation of the methylation level. It is also noteworthy that the bisulfite conversion technique cannot be used to discriminate the methylated cytosine from 5-hydroxymethylcytosine \[[@R34]\]. Second, the false positives may be caused by multiple comparison when we compared various CpG sites between groups. We used the Bonferroni correction method to adjust for the test level; however, this is an overcorrection when the tests are correlated \[[@R35]\]. Third, aberrant DNA methylation usually occurs somatically in cancer cells and can also be detected in peripheral blood samples \[[@R36]\]. To evaluate the clinical use of aberrant DNA methylation, a blood-based assay is preferable, since it uses a far less invasive procedure.

In conclusion, aberrant DNA methylation is a promising biomarker that has a good predictive value for identifying esophageal cancer in a molecular diagnostic laboratory. The hypermethylation status of *PRDM16, PIK3R1,* and *CDKN2A* genes might be used as a potential biomarker for the diagnosis of ESCC.

MATERIALS AND METHODS {#s4}
=====================

Study design {#s4_1}
------------

First, we used the Illumina Infinium 450K Methylation Beadchip to construct a genome-wide DNA methylation profile. Then, candidate genes were selected for the validation using the Next-Generation Sequencing (NGS) platform (Illumina MiSeq platform).

Study subjects {#s4_2}
--------------

This study was approved by the Ethics Committee of Nanjing Medical University. Written informed consent was obtained from all participants. The methods were carried out in accordance with the approved guidelines. Esophageal cancer patients were recruited in the Yangzhong People\'s Hospital from 2012 to 2016. Yangzhong is an area with high morbidity and mortality rates of the upper digestive tract cancers \[[@R37]\]. The inclusive criteria were: (1) Patients were diagnosed as ESCC with histopathological evidence; (2) All patients were of Chinese Han origin living in Yangzhong longer than five years; (3) Patients underwent esophagectomy and the lesions were eligible for sampling; (4) None of the patients had received preoperative radiotherapy or chemotherapy. Tissues in the center of the cancer lesion and remote normal-appearing esophagus were excised and immediately stored in -80°C freezer. Healthy control esophageal tissues were collected from individuals who had no cancer history and participated in a screening program for upper digestive tract cancers.

DNA extraction {#s4_3}
--------------

Genomic DNA was extracted from tissues using the QIAmp DNA Mini Kit (Qiagen, Hilden, Germany). The quality and concentration were evaluated with Thermo NanoDrop 2000-1 spectrophotometer (NanoDrop Technologies, Montchanin, DE, USA).

Infinium methylation 450K array {#s4_4}
-------------------------------

We used the Infinium 450K Methylation Beadchip (Illumina, San Diego, CA, USA) to evaluate the methylation status of five paired tumor samples and corresponding remote normal-appearing esophagus tissues, along with two normal controls from the healthy population.

Next-generation sequencing (NGS) {#s4_5}
--------------------------------

### Primer design and optimization {#s4_5_1}

Genomic regions were analyzed and transformed to bisulfite-converted sequences by gene CpG software. The primers were designed by the Gensky Bio-Tech Co., Ltd. (Shanghai) to amplify regions of interest from the bisulfite converted DNA. Different sets of primers were compared using 1 ng bisulfite modified positive and negative control DNA samples. The final optimized primers are listed in Table [5](#T5){ref-type="table"}.

###### Primers designed for multiplex PCR

  Genes        Fragment                        Forward primer                      Reverse primer
  ------------ ------------------------------- ----------------------------------- ------------------------------
  RASSF1       RASSF1_M1                       AAGGAGGGAAGGAAGGGTAAG               CCAACTCCCRCAACTCAATAAAC
  RASSF1_M2    GGGGAGTTTGAGTTTATTGAGTTG        CCCAAATAAAATCRCCACAAAAATC           
  RASSF1_M3    GATTTTTGTGGYGATTTTATTTGG        TACATATAAACAACCACCTCTACTCATCT       
  RASSF1_M5    GGTAAGYGTATAAGAGTGGTTTTTGGT     AACAAACCACAATACAAACATTCTC           
  RASSF1_M6    GATTTAGTTTTTGTTTTATTGGGGTAG     ACCCAAACTAACCCAAACTCC               
  RASSF1_M7    GTTGTTTTAGGTTATTTYGAAAGAAGG     CTACCCCAATAAAACAAAAACTAAATC         
  RASSF1_M8    GTTAGGAGGGTGGGGTTGTTTA          CCTTCTTTCRAAATAACCTAAAACAAC         
  RASSF1_M9    GGTYGGTTTTAGTTATAGTTGGATAATG    TAAACAACCCCACCCTCCTAAC              
  PIK3R1       PIK3R1_M2                       GTTTGGGGTTGGTTGAAAGAT               CCTAACRAACCCTTCCTACCAC
  PIK3R1_M4    TGGAGYGGAGTTGGAGGAAGTAG         CACACCCRAAACTACTACTACCTACCTA        
  PIK3R1_M5    GGAAAYGGGAGTTAGGATGG            CAACAACAACCCCRAATATATATACTC         
  PIK3R1_M6    GTAGYGATTTTGGTTGTAGTTGGAG       CCATCCTAACTCCCRTTTCC                
  PIK3R1_M7    TTTYGTGGTTTTTTAGTTGTAGTTAGG     CCAACAACCTACCCAAACTTAAC             
  PIK3R1_M8    GAAATTTAGTTGGTTTTTTAATGAGGA     ACCTCCCCCCAACCTATTC                 
  ITGAV        ITGAV_M1                        TTGAGAGGTAGGATGGGTGAG               TCTTCTCTCRAAACTCCTACTACCTCT
  ITGAV_M2     AGGTAGTAGGAGTTTYGAGAGAAGAAG     AAACTCAACCCTCTTACCTACCC             
  ITGAV_M3     GGGGTAGGTAAGAGGGTTGAG           ACTCCTCCTCCTTCCAAATCTC              
  NFKB1        NFKB1_M2                        GGGGTAGGAAGAGGAGGTTT                AACCRAACCAAACCAATCAAC
  NFKB1_M3     GTTGATTGGTTTGGTTYGGTT           CCCTACCRAACCCCCACT                  
  NFKB1_M4     GGGAGGAGGTTGATAGTAGTTGAG        CACTCCAACCTTCTCACCATC               
  TAP2         TAP2_M1                         GGTGGTTTAYGTTTGTAATTATAGTATTTTG     CTCACTCTTATCRCCCAAACTAAAATAC
  TAP2_M2      GTTAAGGTTTTTATTTTGGGTTGG        TCTCCAATTACAAAACATTCTCCA            
  TAP2_M3      GGAGTGGGTAGTTATTTGGGTTG         CCAACCCAAAATAAAAACCTTAAC            
  APC          APC_M2                          GGGTTAGGGTTAGGTAGGTTGTG             CATTCTATCTCCAATAACACCCTAAC
  BRCA1        BRCA1_M1                        GGGAGGAATTTTGTAAAGAAGAGG            ACRAACTAAAAAACTCCTCCAACAC
  BRCA1_M2     GGGGAGGYGGTAATGTAAAGAT          ACCCCTCAACCCCAATATTTA               
  BRCA1_M3     AGTGATGTTTTGGGGTATTGG           AAACTCCTAACCTCATAACCAACC            
  BRCA1_M4     GAGGTTAGGAGTTTTAGATTAGTTTGATT   CCATCCTCTCATACATACCAACC             
  CCND1        CCND1_M3                        TAGGGTTTGATTTTYGTTTGTAGG            AAAACCCCAAAAATTCAAACTC
  CDH1         CDH1_M1                         GGAATTGTAAAGTATTTGTGAGTTTG          CTCCTCAAAACCCRAACTTTCT
  CDKN2A       CDKN2A-2                        GGGATATGGAGGGGGAGAT                 CTTCTTCCTCTTTCCTCTTCCC
  CDKN2A-4     AATAAAATAAGGGGAATAGGGGAG        CCATCTTCCCACCCTCAA                  
  CDKN2A-6     GTAGTTAAGGGGGTAGGAGTGG          ACTACTACCCTAAACRCTAACTCCTCAA        
  CDKN2A-7     TTGAGGAGTTAGYGTTTAGGGTAGTAGT    TCAATAATACTACRAAAACCACATATCTAAATC   
  CDKN2A_M8    GTTTTTTAGGTTGGAGTGTAATGG        TCTATAATCCCAACATTCTAAAAAACC         
  CDKN2A_M9    TTAGAGGATTTGAGGGATAGGGT         AACCAATCAACCRAAAACTCC               
  CDKN2A_M10   GGAGTTTTYGGTTGATTGGTT           CCCAAAAAACCTCCCCTTT                 
  BNIP3        BNIP3-1                         GGTAAYGTGGATTTTGAGGTTGT             CCATCCTCCCCTTCCRTAC
  BNIP3-3      GGTTGYGGGATGTGTTTTAGTT          CAAACCTCTACCCCTCRCCC                
  BNIP3-6      GGTGGGTYGGAGTTGAGYGT            TACACCRCRAAAACCCCTTAC               
  BNIP3-7      GTAAGGGGTTTTYGGGGTGTA           CCTCTAAAAAATACCTCCCAATCC            
  HTATIP2      HTATIP2-1                       TTTGGGTGAGTTGAGTTTAGTAGG            AAACATCCCACCTTCCCTAA
  HTATIP2-2    TTAGGGAAGGTGGGATGTTT            ACTACTAACATCACTAAACATACCCCAC        
  PRDM16       PRDM16-1                        GGTAGGGAATGGGGTTGTG                 CTAAACCTTCTACCTTAAATCCTCC
  PRDM16-2     GGAGGATTTAAGGTAGAAGGTTTAG       ACTCCTAACCTTACCCTCCCTAC             
  PRDM16-3     GTAGGGAGGGTAAGGTTAGGAGT         AATAACCCRAACCCAAAAACCT              
  PRDM16-4     AGGTTTTTGGGTTYGGGTTATT          AACTAAACCACCTTCRAAAACCC             
  PRDM16-5     GGGTTTTYGAAGGTGGTTTAGTT         CTCCRCCACTACCCAAAC                  
  PRDM16-7     GAGGGGAGAATGTAGGAGAAAAG         CTACTACTCCCRCCCCAACC                
  PRDM16-8     GGTTGGGGYGGGAGTAGTAG            CACTTATCTCTCCCCCCTCTC               
  PRDM16-9     GAGAGGGGGGAGAGATAAGTG           CACTATCTTCATCTCCCCAACA              
  PTEN         PTEN-1                          TTAGGGAGGGGGTTTGAGT                 CTCCTCAACAACCAAAAACCTAA
  PTX3         PTX3-1                          GTAGGTTTGGGYGGGTTGTT                TCCAAAACACTAATCAACCTAACCT
  PTX3-2       AGGTTAGGTTGATTAGTGTTTTGGA       CTCCTTACCTACCRACAACCAA              
  SOCS1        SOCS1-1                         GGGGAGGGTATTTATATGGTTTTA            ACTAAAAACCCCRCTACRCCAAC
  SOCS1-2      GTTGGYGTAGYGGGGTTTTTAGT         CCTACRAATTCTACTAAAAACCCCTAA         
  SOCS1-3      TTAGGGGTTTTTAGTAGAATTYGTAGG     CAATCTCCACAACAACAAAACC              

Bisulfite conversion and multiplex amplification {#s4_6}
------------------------------------------------

Genomic DNA (about 400 ng) was subjected to sodium bisulfite modification using EZ DNA Methylation™-GOLD Kit (Zymo Research, Orange, CA, USA) according to the manufacturer\'s protocols. An un-methylated cytosine was converted to uracil when treated with bisulfite, whereas a methylated cytosine remained as cytosine \[[@R38]\]. A multiplex PCR was performed using the optimized primer sets. A 20 μl PCR reaction mixture was prepared for each reaction, including 1x buffer (TaKaRa, Tokyo, Japan), 3 mM Mg^2+^, 0.2 mM dNTP, 0.1 μM of each primer, 1U HotStarTaq polymerase (TaKaRa, Tokyo, Japan) and 2 μl of template DNA. The cycling program was 95°C for 2 min; 11 cycles of 94°C for 20 sec, 63°C for 40 sec with a decreasing temperature step of 0.5°C per cycle, 72°C for 1 min; then followed by 24 cycles of 94°C for 20 sec, 65°C for 30 sec, 72°C for 1 min; 72°C for 2 min.

Index PCR and sequencing {#s4_7}
------------------------

PCR amplicons were then diluted and amplified using the indexed primers. Specifically, a 20 μl mixture was prepared for each reaction, including 1x buffer (NEB, MA, USA), 0.3 mM dNTP, 0.3 μM forward primer, 0.3 μM index primer, 1 U Q5^TM^ DNA polymerase (NEB, MA, USA) and 1 μL of diluted template (PCR amplicons from the previous step). The cycling program was 98°C for 30 sec; 11 cycles of 98°C for 10 sec, 65°C for 30 sec, 72°C for 30 sec; 72°C for 5 min. The PCR products (170 bp −270 bp) were separated by agarose electrophoresis and purified using the QIAquick Gel Extraction kit (Qiagen, Hilden, Germany). Libraries from different samples were quantified and pooled together, followed by sequencing on the Illumina MiSeq platform according to the manufacturer\'s protocols. Sequencing was performed with a 2 × 300 bp paired-end mode. Quality control of sequencing-reads was performed by FastQC (<http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/>). Filtered-reads were aligned back to the reference genome using the Bismark software (<http://www.bioinformatics.babraham.ac.uk/projects/bismark/>). After reads recalibration withUSEARCH \[[@R39]\], the methylation and haplotype were analyzed using the Perl script.

Immunohistochemistry {#s4_8}
--------------------

Sections (4 μm) of formalin fixed, paraffin embedded tissues were prepared. The slides were dried at 56°C for 1 hour, then deparaffinized with fresh xylene and rehydrated through ethanol washes. Antigen retrieval was performed by citrate buffer incubation (pH 6.0) using a microwave oven for 10 min at 100°C. Slides were incubated for 15 min with 3% hydrogen peroxide, washed in PBS, and incubated with an appropriate primary antibody followed by a secondary antibody. Sections were counterstained, and examined by fluorescence microscopy. Antibodies and dilutions used in immunocytochemistry were as follows: rabbit anti-PTEN (1:100); rabbit anti-RASSF1 (1:100); rabbit anti- PIK3R1 (1:100); rabbit anti IgG (1:400). The integrated optical density (IOD) was calculated for each sample \[[@R40]\]. For semi-quantitative analysis of the degree of staining, slides were independently scored by two pathologists. The scores were defined as follows: 0 (\< 5% positive tumor cells); 1 (≤ 25% positive tumor cells); 2 (26--50% positive tumor cells); 3 (51--75% positive tumor cells); and 4 (\> 75% positive tumor cells). Staining intensity was graded as: 0 (no staining); 1 (weak staining: light yellow); 2 (moderate staining: yellow brown); and 3 (strong staining: brown). Staining index (SI) was calculated as the product of staining intensity score and the proportion of positive tumor cells \[[@R41]\]. An SI score of 9--12 indicated strong positive (+++); 5--8 indicated positive (++); 1--4 indicated weakly positive (+); 0 indicated negative (−) staining.

Statistical analysis {#s4_9}
--------------------

We used the IBM SPSS Statistics 19.0 (IBM Corp., NY, USA) and the R program (<https://www.r-project.org/>) to analyze the data. Individual and cumulative methylation statuses of candidate genes were analyzed. We used the *t-test*, ANOVA or nonparametric test to compare the differences of methylation between groups. Considering the false positive caused by multiple comparisons, the Bonferroni correction was applied. The receiver operative characteristics (ROC) curve was drafted to reflect the diagnostic value of biomarkers. The area under the curve (AUC) together with 95% confidence interval (CI) were calculated.
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